Literature DB >> 17442977

Interactions between CD47 and thrombospondin reduce inflammation.

Laurence Lamy1, Arnaud Foussat, Eric J Brown, Paul Bornstein, Michel Ticchioni, Alain Bernard.   

Abstract

CD47 on the surface of T cells was shown in vitro to mediate either T cell activation or, in the presence of high amounts of thrombospondin (TSP), T cell apoptosis. We report here that CD47-deficient mice, as well as TSP-1 or TSP-2-deficient mice, sustain oxazolone-induced inflammation for more than four days, whereas wild-type mice reduce the inflammation within 48 h. We observe that prolonged inflammation in CD47-, TSP-1-, or TSP-2-deficient mice is accompanied by a local deficiency of T cell apoptosis. Finally, we show that upon activation normal T cells increase the expression of the proapoptotic Bcl-2 family member BNIP3 (Bcl-2/adenovirus E1B 19-kDa interacting protein) and undergo CD47-mediated apoptosis. This finding is consistent with our previous demonstration of a physical interaction between BNIP3 and CD47 that inhibits BNIP3 degradation by the proteasome, sensitizing T cells to CD47-induced apoptosis. Overall, these results reveal an important role in vivo for this new CD47/BNIP3 pathway in limiting inflammation by controlling the number of activated T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442977     DOI: 10.4049/jimmunol.178.9.5930

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

1.  Antigen-induced regulation of T-cell motility, interaction with antigen-presenting cells and activation through endogenous thrombospondin-1 and its receptors.

Authors:  Sten-Erik Bergström; Mehmet Uzunel; Toomas Talme; Eva Bergdahl; Karl-Gösta Sundqvist
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

Review 2.  The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47.

Authors:  David D Roberts; Thomas W Miller; Natasha M Rogers; Mingyi Yao; Jeffrey S Isenberg
Journal:  Matrix Biol       Date:  2012-01-14       Impact factor: 11.583

Review 3.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

4.  Novel role of CD47 in rat microvascular endothelium: signaling and regulation of T-cell transendothelial migration.

Authors:  Roberta Martinelli; Gail Newton; Christopher V Carman; John Greenwood; Francis W Luscinskas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-08-29       Impact factor: 8.311

Review 5.  Thrombospondins in the transition from myocardial infarction to heart failure.

Authors:  Jonathan A Kirk; Oscar H Cingolani
Journal:  J Mol Cell Cardiol       Date:  2015-12-10       Impact factor: 5.000

Review 6.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

7.  A novel cancer therapeutic using thrombospondin 1 in dendritic cells.

Authors:  Tzu-Yang Weng; Shih-Shien Huang; Meng-Chi Yen; Chi-Chen Lin; Yi-Ling Chen; Chiu-Mei Lin; Wei-Ching Chen; Chih-Yang Wang; Jang-Yang Chang; Ming-Derg Lai
Journal:  Mol Ther       Date:  2013-10-15       Impact factor: 11.454

Review 8.  Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease.

Authors:  Natasha M Rogers; Kedar Ghimire; Maria J Calzada; Jeffrey S Isenberg
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

9.  Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.

Authors:  Thomas W Miller; Sukhbir Kaur; Kelly Ivins-O'Keefe; David D Roberts
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 10.  The Neuro-Immune-Regulators (NIREGs) Promote Tissue Resilience; a Vital Component of the Host's Defense Strategy against Neuroinflammation.

Authors:  Yosra Bedoui; Jim W Neal; Philippe Gasque
Journal:  J Neuroimmune Pharmacol       Date:  2018-06-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.